drugset / Trial / NCT00737360
Phase II Study of TAS-106 to Treat Head and Neck Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.
Timeline
- Start
- 2008-08
- Primary completion
- 2011-06
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAS-106 | Small molecule | 6.5 mg/m2 | Intravenous |